Kinase activation by chromosomal translocations is a common mechanism that drives tumorigenesis in spitzoid neoplasms. To explore the landscape of fusion transcripts in these tumors, we performed whole-transcriptome sequencing using formalin-fixed, paraffin-embedded (FFPE) tissues in malignant or biologically indeterminate spitzoid tumors from 7 patients (age 2-14 years). RNA sequence libraries enriched for coding regions were prepared and the sequencing was analyzed by a novel assembly-based algorithm designed for detecting complex fusions. In addition, tumor samples were screened for hotspot TERT promoter mutations, and telomerase expression was assessed by TERT mRNA in situ hybridization (ISH). Two patients had widespread metastasis and subsequently died of disease, and 5 patients had a benign clinical course on limited follow-up (mean: 30 months). RNA sequencing and TERT mRNA ISH were successful in six tumors and unsuccessful in one disseminating tumor because of low RNA quality. RNA sequencing identified a kinase fusion in five of the six sequenced tumors: TPM3-NTRK1 (2 tumors), complex rearrangements involving TPM3, ALK, and IL6R (1 tumor), BAIAP2L1-BRAF (1 tumor), and EML4-BRAF (1 disseminating tumor). All predicted chimeric transcripts were expressed at high levels and contained the intact kinase domain. In addition, two tumors each contained a second fusion gene, ARID1B-SNX9 or PTPRZ1-NFAM1. The detected chimeric genes were validated by home-brew break-apart or fusion fluorescence in situ hybridization (FISH). The two disseminating tumors each harbored the TERT promoter -124C>T (Chr 5:1,295,228 hg19 coordinate) mutation, whereas the remaining five tumors retained the wild-type gene. The presence of the -124C>T mutation correlated with telomerase expression by TERT mRNA ISH. In summary, we demonstrated complex fusion transcripts and novel partner genes for BRAF by RNA sequencing of FFPE samples. The diversity of gene fusions demonstrated by RNA sequencing defines the molecular heterogeneity of spitzoid neoplasms.
Kinase activation by chromosomal translocations is a common mechanism that drives tumorigenesis in spitzoid neoplasms. To explore the landscape of fusion transcripts in these tumors, we performed whole-transcriptome sequencing using formalin-fixed, paraffin-embedded (FFPE) tissues in malignant or biologically indeterminate spitzoid tumors from 7 patients (age 2-14 years). RNA sequence libraries enriched for coding regions were prepared and the sequencing was analyzed by a novel assembly-based algorithm designed for detecting complex fusions. In addition, tumor samples were screened for hotspot TERT promoter mutations, and telomerase expression was assessed by TERT mRNA in situ hybridization (ISH). Two patients had widespread metastasis and subsequently died of disease, and 5 patients had a benign clinical course on limited follow-up (mean: 30 months). RNA sequencing and TERT mRNA ISH were successful in six tumors and unsuccessful in one disseminating tumor because of low RNA quality. RNA sequencing identified a kinase fusion in five of the six sequenced tumors: TPM3-NTRK1 (2 tumors), complex rearrangements involving TPM3, ALK, and IL6R (1 tumor), BAIAP2L1-BRAF (1 tumor), and EML4-BRAF (1 disseminating tumor). All predicted chimeric transcripts were expressed at high levels and contained the intact kinase domain. In addition, two tumors each contained a second fusion gene, ARID1B-SNX9 or PTPRZ1-NFAM1. The detected chimeric genes were validated by home-brew break-apart or fusion fluorescence in situ hybridization (FISH). The two disseminating tumors each harbored the TERT promoter -124C>T (Chr 5:1,295,228 hg19 coordinate) mutation, whereas the remaining five tumors retained the wild-type gene. The presence of the -124C>T mutation correlated with telomerase expression by TERT mRNA ISH. In summary, we demonstrated complex fusion transcripts and novel partner genes for BRAF by RNA sequencing of FFPE samples. The diversity of gene fusions demonstrated by RNA sequencing defines the molecular heterogeneity of spitzoid neoplasms. Modern Pathology (2016) 29, 359-369; doi:10.1038/modpathol.2016.37; published online 19 February 2016 Spitzoid tumors are a clinicopathologically distinct class of melanocytic neoplasms that occur more commonly in younger individuals and account for the majority of so-called 'melanomas' seen in the pediatric population. Histologically, these lesions are characterized by compound or dermal proliferations of large epithelioid and/or spindle-shaped melanocytes having abundant eosinophilic cytoplasm, often forming junctional nests in conjunction with epidermal hyperplasia. The lack of objective criteria to determine the malignant potential of spitzoid tumors is a major diagnostic challenge. [1] [2] [3] [4] [5] The established histopathologic criteria used to differentiate nevi from conventional melanoma are not reliable for spitzoid neoplasms. Also, unlike conventional melanoma, lymph node metastasis in general is not predictive of poor clinical outcome in patients with spitzoid tumors. [6] [7] [8] [9] [10] [11] [12] [13] Spitzoid lesions with features significantly deviating from a stereotypical Spitz nevus, such as large lesional size (41 cm), asymmetry, ulceration, pagetoid melanocytosis extending peripherally, significant intradermal mitotic activity, lack of cellular maturation with depth, confluent cellular growth, involvement of subcutaneous fat, or severe cytologic atypia, are considered atypical spitzoid melanocytic proliferations, encompassing atypical Spitz tumor and spitzoid melanoma. Additional important clinical information includes the age of the patient, as melanoma is extremely rare under the age of 10 years, and clinical features such as a new or rapidly growing lesion, asymmetry, irregular coloration, ulceration, bleeding, and history of trauma. The diagnosis of spitzoid melanoma in these circumstances is considered when multiple chromosomal aberrations are detected by using ancillary molecular techniques, such as the multiprobe fluorescent in situ hybridization (FISH) assay 14, 15 or comparative genomic hybridization analysis. 16, 17 The true predictive value of these assays for determining clinical outcome in spitzoid tumors, however, remains uncertain. We recently evaluated 56 spitzoid tumors for the presence of telomerase reverse transcriptase (TERT) promoter mutations and their association with disease progression. We found a hotspot TERT promoter mutation in tumors from patients who had a malignant clinical course but not in tumors from patients who had a favorable clinical outcome, suggesting that these mutations contribute to malignant biological behavior. 12 Nonetheless, the underlying molecular mechanisms responsible for the potential of these lesions to spread distantly need to be investigated further.
The Cancer Genome Atlas Network has recently proposed a genomic classification of cutaneous melanomas into four mutually exclusive genetic subtypes on the basis of the presence of a hotspot mutation in the significantly mutated melanoma-associated genes, BRAF, RAS (N/K/H), NF1, and the triple wild-type. 18 By this stratification scheme, most spitzoid melanomas are likely to fall into the triple wild-type subtype, 19, 20 a heterogeneous molecular category shown to be enriched by focal amplifications or complex structural rearrangements. 18 Wiesner et al. and others [21] [22] [23] [24] demonstrated that instead of activation of the MAP kinase pathway through point mutations, chromosomal translocation-induced kinase fusions drive tumorigenesis in spitzoid neoplasms. These rearrangements are predicted to constitutively activate the MAP kinase pathway by an in-frame fusion of the receptor tyrosine kinase NTRK1, ROS1, RET, ALK, or MET or the serine/threonine kinase BRAF to the N terminal of various 5′ partner genes. 21, 23, 24 As these genetic alterations are present in the entire biologic spectrum of the disease, that is, the benign (nevi), the biologically indeterminate or low-grade malignant (atypical Spitz tumors), and the overtly malignant lesions (spitzoid melanoma), they are likely acquired in the early stage of disease but cannot by themselves lead to melanoma. 25, 26 To explore the landscape of structural rearrangements in spitzoid melanomas, in the current study we used RNA sequencing to characterize the transcriptome of seven histologically malignant or biologically indeterminate spitzoid tumors. Furthermore, we used TERT mRNA in situ hybridization (ISH) to demonstrate the association between TERT promoter mutations and telomerase expression at the cellular level.
Materials and methods

Study Population
The study was approved by the institutional review boards of participating institutions. The study subjects were selected from a previously reported cohort of 56 patients with spitzoid melanocytic tumors 12 for whom documented clinical outcomes and sufficient biological material were available. To improve the performance of RNA sequencing, only biological samples with a storage time of ≤ 7 years were considered for the study. As an exception, an old archived formalin-fixed, paraffin-embedded (FFPE) block (420 years old) from a rare fatal spitzoid melanoma in a young patient was also included. Adequate biologic material was obtained for RNA sequencing from seven malignant or biologically indeterminate spitzoid tumors (five primary tumors and two metastatic tumors).
The hotspot BRAF, NRAS, and TERT promoter mutation data on these tumors have been previously reported. 12 In summary, genomic DNA was extracted from the tumor samples (five primary tumors, one paired primary and metastatic tumor, and one metastatic tumor) and screened for hotspot mutations of the genes by PCR and Sanger sequencing, as previously described. 20 
Transcriptome Sequencing
Tumor tissue samples from 8 to 10 FFPE slide-mounted sections were manually dissected, with corresponding H&E sections used to guide dissections, to obtain at least 70% tumor purity. RNA was isolated by using the Maxwell system (Promega). RNA was quantitated by fluorescence dye staining by using the Quant-iT (Life Technologies) RNA assay. RNA quality was evaluated by using a 2100 Bioanalyzer (Agilent Technologies) with a Nano RNA 6000 Chip. RNASEQ libraries enriched for coding regions were prepared by using the Truseq RNA Access Library Prep Kit (Illumina), following the manufacturer's protocol for RNA input quantity relative to RNA quality. Sequencing was performed on HiSeq2000 (Illumina) to generate 100-bp paired-end reads.
RNA Sequencing Analysis
RNA sequencing data were generated as previously described. 25 Paired-end reads from RNA sequences were aligned to the following 4 database files by using BWA (0.5.10) aligner: (1) the human GRCh37-lite reference sequence, (2) RefSeq, (3) a sequence file representing all possible combinations of nonsequential pairs in RefSeq exons, and (4) an AceView database flat file downloaded from UCSC, representing transcripts constructed from human expressed sequence tags. The mapping results from files 2, 3, and 4 were aligned to human reference genome coordinates and also to the human GRCh37-lite reference sequence by using STAR 2.3.0 without annotations. The final BAM file was constructed by selecting the best alignment among the five mappings. The coverage was calculated by using an in-house pipeline. Structural variations were detected by using CICERO, a novel algorithm that uses de novo assembly to identify structural variations in RNA sequences.
Fluorescence In Situ Hybridization BAC clones (BACPAC Resources) were used to develop break-apart probes for the following genes:
. Break-apart FISH for ALK was performed by using a commercially available probe set (CytoCell, Cat. no. LPS 019-A). In addition, BAC clones (CH17-132B19, RP11-99L10 and CH17-57M15, CH17-240N01) were used to develop a fusion probe set for PTPRZ1-NFAM1. Dual-color FISH was performed on 4 μm FFPE sections, as previously described. 20 TERT mRNA ISH
The mRNA ISH, a novel method to detect mRNA in FFPE tissues, 26 was performed for TERT mRNA on a Discovery Ultra automation system (Ventana Medical Systems) by using RNAscope VS Reagent Kit-RED (Advanced Cell Diagnostics). VS Probe-Hs-TERT (Cat. no.605516) specific to the sequence region between nucleotides 2164 and 3231 encoding the TERT transcript was used according to the manufacturer's instructions. Briefly, 4 μm FFPE tissue sections of tumors were pretreated in citrate buffer with heat, followed by protease digestion before hybridization with the target oligo probes. Slides were hybridized sequentially with target probes incubated at 43°C for 2 h and 32 min, preamplifier at 53°C for 32 min, and amplifier at 53°C for 32 min, and label probes at room temperature for 12 min. Between the hybridization steps, slides were washed with Ribowash buffer (0.1 × saline sodium citrate). Hybridization signals were detected by chromogenic development with Fast Red, followed by counterstaining with hematoxylin. Each sample was quality controlled for RNA integrity with an RNAscope probe for PPIB RNA and for background with a probe for bacterial dapB RNA. The specific RNA staining signal was identified as intracellular red punctate dots. and involved the lower extremities (n = 5), ear (n = 1), and trunk (n = 1). Two patients had clinically detectable lymphadenopathy (macrometastasis). Of the 6 patients whose sentinel/regional lymph nodes were examined, 5 patients were positive for nodal metastasis (Table 1) , with clinically detectable lymphadenopathy (patients 5 and 7), large nodal deposits (patients 2 and 3), and isolated tumor cells (patient 1). At a median follow-up of 20 months (range, 6-72 months), 5 patients were alive and well 
Results
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RNA-seq in spitzoid tumors
with no evidence of disease and 2 patients developed distant metastasis in the lungs and brain and subsequently succumbed to the disease 18 and 24 months after diagnosis (Table 1) .
BRAF, NRAS, and TERT Promoter Mutations
The seven spitzoid tumors were negative for the activating point mutations in BRAF and NRAS. The two tumors that led to a fatal outcome each harbored a TERT promoter mutation at -124 bp from the ATG start site (-124C>T) in the primary and metastatic samples, whereas the five other tumors retained the TERT promoter wild type (Table 1) .
Fusion Transcripts by RNA Sequencing
RNA sequencing was successful in 6 of the 7 samples, with a minimum 20 × coverage of at least 20% exonic bases and a median coverage of 10 × in all RefSeq annotated exons ( Supplementary Table 1 ). Coverage was low in one sample obtained from old FFPE material (patient 7), and it was excluded from analysis. RNA sequencing identified a kinase fusion in five of the six successfully tested tumors (Supplementary Table 2 ). The following fusion genes were identified by RNA sequencing: EML4-BRAF (1 disseminating tumor; Figure 1 ), BAIAP2L1-BRAF (1 tumor; Figure 2 ), TPM3-NTRK1 (2 tumors; Figure 3 ), and TPM3-ALK (1 tumor; Figure 4 ). All predicted chimeric transcripts were expressed at high levels and contained the intact kinase domain. The FPKM (fragment per kb per million mapped reads) expression values for the fusion genes are provided in Supplementary Table 2 . In addition, two spitzoid tumors each carried a second fusion gene, ARID1B-SNX9 and PTPRZ1-NFAM1 ( Supplementary  Figure 1 ). There was no structural rearrangement in one of the successfully sequenced samples (patient 6). 
Fluorescence In Situ Hybridization
Break-apart FISH for BRAF (2 tumors), NTRK1 (2 tumors), PTPRZ1 (1 tumor), IL6R (1 tumor), TPM3 (3 tumors), EML4 (1 tumor), ARID1B (1 tumor), and BAIAP2L1 (1 tumor) showed split signals in at least 30% of the evaluated cells, indicating rearrangement of the respective genes (Figures 1, 2, 3 and 4 and Supplementary Figure 1) . The PTPRZ1-NFAM1 fusion FISH showed multiple copies of overlapping signals ( Supplementary Figure 1 ), suggesting gene fusion followed by copy gain in the kinase fusion gene.
TERT mRNA ISH TERT mRNA ISH showed distinct bright intracellular signals in melanocytes in the TERT promoter mutant metastasizing tumor ( Figure 1) but not in the wildtype TERT promoter tumors (Figure 2 ). TERT mRNA ISH was not successful in one sample (patient 7) because of low RNA quality.
Discussion
By using RNA sequencing, we identified in-frame fusions of kinases, BRAF, NTRK1, and ALK, in a mutually exclusive pattern, with various partner genes in five of the six successfully sequenced spitzoid tumors. We found two novel 5′ BRAF fusion partners EML4 and BAIAP2L1, expanding the list of BRAF N-terminal fusion partners previously described in pilocytic astrocytoma and melanocytic tumors. [21] [22] [23] 27 EML4 is a recurrent fusion partner gene with ALK, and the resulting fusion transcript EML4-ALK is the primary oncogenic driver in 3-6% of non-small-cell lung carcinomas. 28, 29 However, to our knowledge, there are no reports of EML4 participating in an oncogenic fusion with BRAF. BAIAP2L1 (BAI1-associated protein 2-like 1) has been reported to participate in the fusion transcript with FGFR3 in bladder and lung cancer, but has never been described previously in melanoma. [30] [31] [32] One of the samples in our study (patient 4) harbored the TPM3-ALK fusion that has been previously reported in spitzoid neoplasms. 33, 34 Interestingly, before the discovery of its oncogenic association with melanocytic neoplasms, TPM3-ALK was identified in tumors from other lines of differentiation, namely the mesenchymal (inflammatory myofibroblastic tumor), 35 the lymphoid (anaplastic large-cell lymphoma), 36 and the epithelial (squamous cell carcinoma and renal cancer) lineages. 37, 38 This finding supports the assertion that known fusion genes can drive oncogenesis in tumors of different cell types. In addition to translocations, ALK is also activated through a de novo alternative transcription initiation, without genetic alterations at the ALK locus, in ∼ 11% of melanomas. 39 Certain morphologic features have been linked to spitzoid tumors with ALK rearrangement. 24, 34 Similar features were seen in our patient sample with ALK fusion that exhibited nests of spindle-shaped melanocytes with fascicular infiltration of the dermis and subcutis (Figure 4 ). Although no definitive conclusions can be drawn because of the small number of samples in this study, the two samples with NTRK1 fusion shared a few morphologic features such as prominent cellularity, deep extension, nested arrangement in the upper part, and confluent cellular nodules with rounded pushing margins at the bottom (Figure 3 ). How reliably these morphologic manifestations predict the type of fusion transcripts has not yet been sufficiently studied. In any case, given the diversity of gene fusions involving alternative partners or even alternative exons within the same pairs of genes, as demonstrated in two spitzoid melanomas in this series harboring TMP3-NTRK1 (Figure 3 ), or other coexisting genetic alterations, the morphologic heterogeneity in spitzoid tumors even with the same kinase fusion is not unexpected.
Of the two patients with fatal outcomes in our study, one carried a BRAF fusion and the sample from the other patient could not be successfully sequenced because of degraded RNA. The second patient with BRAF fusion in our series had a benign course of disease. To date, the association between the type of fusion gene and prognosis in patients with spitzoid tumors remains uncertain. Tumors from both patients with fatal outcomes harbored the -124C>T transcriptional activating mutation in the TERT promoter. The -124C>T mutation (also referred to as C228T in the literature) has been previously shown to correlate with high TERT mRNA expression in melanoma, 18 and here on a different platform using TERT mRNA ISH, we demonstrated its association with telomerase expression at a cellular level (Figure 1) .
Transcriptome sequencing identified additional novel fusion genes accompanied with kinase fusions in spitzoid tumors. One sample harbored the PTPRZ1-NFAM1 that was associated with elevated expression of the NFAT activated protein with ITAM motif 1 (NFAM1) (FPKM = 621.2). The protein encoded by NFAM1 contains an immunoreceptor tyrosine-based activation motif that is thought to regulate the development of B cells, 40 but its role in cancer development and melanoma is not well studied. The 5′ partner gene PTPRZ1 is a recurrent fusion partner with MET in glioblastoma. 41 The fusion transcript ARID1B-SNX9 is expected to lead to the loss of function of the tumor suppressor gene ARID1B, a subunit of the SWI/SNF complex. Although the exact function of ARID1B in melanoma has not been investigated, 13% of melanomas have a loss-of-function mutation in a component of the SWI/SNF complex, 42 suggesting that the chromatin remodeling complex plays a role in melanoma tumorigenesis. Although the oncogenic contribution of these genetic alterations remains speculative until they are functionally characterized, our findings, together with the complex nature of translocation events seen in the tumor samples, suggest that spitzoid tumors are enriched with structural rearrangements.
Notably, no structural rearrangement was identified in one spitzoid tumor in our study ( Table 1 ; patient 6), even though the exonic coverage for this sample was comparable to that of other specimens ( Supplementary Table 1 ). Therefore, we speculate that in a subset of spitzoid neoplasms, mechanisms other than translocations can activate oncogenes. Whole-genome sequencing can give further insights into the oncogenic mechanisms of these tumors.
In summary, we demonstrate complex and heterogeneous structural rearrangements in spitzoid tumors by transcriptome sequencing by using FFPE tissue. The heterogeneity of the fusion transcripts observed by RNA sequencing correlates with the morphologic and clinical diversity of this group of melanocytic tumors. The association between TERT promoter mutations or telomerase expression with outcomes in patients with spitzoid melanocytic tumors requires further studies.
